Journal of Immunology Research / 2012 / Article / Tab 2

Clinical Study

Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

Table 2

Objective responses of liver cirrhosis patients with advanced HCC treated after 4–8 weeks of sorafenib treatment.

Dose of sorafenibPRSOPOResponse rate (%)

200 m g (n = 11)
(1 dropout)
0280.0
400 mg (n = 27)
(3 dropout)
411916.7
800 mg (n = 7)
(0 dropout)
13314.3